# Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

> **NCT01229150** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 89 (actual)

## Conditions studied

- Non Small Cell Lung Carcinoma

## Interventions

- **DRUG:** AZD6244
- **DRUG:** Erlotinib
- **DRUG:** AZD6244 + Erlotinib

## Key facts

- **NCT ID:** NCT01229150
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-26
- **Primary completion:** 2013-09-30
- **Final completion:** 2015-11-21
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2017-05-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01229150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01229150, "Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01229150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*